Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company")
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company")
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect
10:00am, Sunday, 15'th Dec 2024
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company")
NEW YORK CITY, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company")
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improveme
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
04:05pm, Wednesday, 13'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
07:00am, Friday, 08'th Nov 2024
— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH —
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
07:00am, Monday, 21'st Oct 2024
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm
09:37pm, Monday, 30'th Sep 2024
NEW YORK , Sept. 30, 2024 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. ("Akero") (NA
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
07:00am, Monday, 30'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious met
Akero Therapeutics: Good Candidate For The MASH Basket
03:37pm, Friday, 20'th Sep 2024
Akero Therapeutics' Efruxifermin (EFX) showed strong results in pre-cirrhotic MASH, but failed in cirrhotic MASH, impacting stock performance. The MASH market is highly competitive with many pipeline
Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
04:05pm, Wednesday, 28'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
11:46am, Friday, 23'rd Aug 2024
NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation s
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
07:00am, Friday, 09'th Aug 2024
-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH
